Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026

Quanterix Corporation (Nasdaq: QTRX), a leader in transforming healthcare through advanced biomarker breakthroughs, has announced it will report its financial results for the fourth quarter and full year of 2025 on March 2, 2026. The company plans to release a press statement with these results prior to an investor conference call scheduled for 4:30 p.m. E.T. on the same day. This call will provide insights into Quanterix’s financial performance and strategic outlook.

Investors can participate in the live call by dialing (800) 715-9871 or (646) 307-1963, using the conference ID 7904928. Additionally, interested parties can join via a live webcast accessible on the company’s website under the Investors section. For those unable to attend, an archived version of the webcast will be made available for one year, ensuring all stakeholders can keep abreast of the company's progress.

Quanterix specializes in ultra-sensitive biomarker detection, which is pivotal for advancements in diagnostics, disease research, and drug development. Utilizing its proprietary technology, Simoa®, Quanterix has gained recognition for its ability to detect and quantify biomarkers in various fluids at unprecedented sensitivity, surpassing traditional detection limits. The company, known for approximately 6,000 peer-reviewed publications, has been a valued ally in scientific research for nearly two decades.

In a significant move during 2025, Quanterix acquired Akoya Biosciences—the Spatial Biology Company®—which enhances its capabilities by integrating multiplexed tissue imaging at single-cell resolution. This acquisition adds value to its offerings, as Quanterix continues to pave the way for precision medicine by bridging the gap between blood biomarkers and tissue analyses.

For more details, visit [Quanterix's website](http://www.quanterix.com).

As Quanterix Corporation (Nasdaq: QTRX) approaches its fourth quarter and full year 2025 financial results announcement on March 2, 2026, investors should closely monitor a few key indicators that may impact market sentiment and stock performance.

Quanterix has positioned itself as a leader in ultra-sensitive biomarker detection, which has vast implications for disease diagnostics and treatment precision. The recent acquisition of Akoya Biosciences adds significant value to its portfolio by enhancing its capabilities in multiplexed tissue imaging. This strategic move aligns with current trends in personalized medicine, creating opportunities for revenue growth and expanding their market share.

As the earnings report draws near, investors should assess the company's previous financial performance, particularly revenue growth rates, profit margins, and cash flow dynamics. It's crucial to analyze how the integration of Akoya has been reflected in revenue composition and operational efficiency. Any positive growth indicators in the press release could bolster stock confidence.

Investors should also be wary of market expectations. Analysts' forecasts or sentiment surrounding Quanterix's future growth and technological advancements could lead to volatility following the earnings announcement. Monitoring the consensus estimates, especially relative to prior quarterly results, can provide insights into trader behavior that may follow the report.

Finally, participation in the live conference call and review of the accompanying webcast will be essential for gaining insights from management regarding future projections and strategic initiatives. Pay special attention to any commentary regarding R&D investment, ongoing partnerships, and pipeline developments, which are critical in a rapidly evolving biotechnology landscape.

In summary, investors should approach Quanterix's upcoming financial results with a keen eye on integration success metrics, market expectations, and management's commentary during the conference call, as these will serve as important indicators of future performance.